评价血液ST13和BCL11B基因表达水平在帕金森病早期诊断中的潜在价值  

Evaluation of ST13 and BCL11B Gene Expression Levels in Early Diagnosis of Parkinson's Disease

作　　者：陆学胜[1] 许敏[1] 张燕[1] 姚胜旗[1] 张允[1] 董强[2] 

机构地区：[1]上海市长宁区中心医院神经内科,上海200336 [2]复旦大学附属华山医院神经内科,上海200040

出　　处：《神经损伤与功能重建》2010年第5期315-319,共5页Neural Injury and Functional Reconstruction

摘　　要：目的:研究外周血ST13和BCL11B基因表达水平作为帕金森病(PD)早期分子诊断标志物的可能性。方法:利用实时定量PCR,比较外周血ST13和BCL11B基因的表达水平在各阶段PD患者中的变化,并计算与健康对照组的统计学差异。结果:PD患者外周血ST13和BCL11B的表达水平明显降低。BCL11B的表达在包括Hoehn-YahrⅠ级患者在内的所有PD患者中均显著下降,而ST13的表达只有在Hoehn-YahrⅡ级以上患者中才出现明显变化。结论:ST13和BCL11B基因表达水平都有作为潜在PD分子诊断标志物的可能,但就筛查早期PD患者而言,BCL11B可能更具优势。Objective：Objective： To explore the possibility of ST13 and BCL11B expression levels as biomarkers in the early molecular diagnosis of Parkinson＇s Disease（PD）.Methods： By real-time PCR,the expression levels of peripheral blood ST13 and BCL11B have been compared in PD patients at different stages.Measurements were also compared with health controls.Results： The expression of peripheral blood ST13 and BCL11B were both expressed at low levels in PD patients.In contrast,the changes in ST13 expression levels were not obvious until PD patients reached Hoehn-Yahr stage II or above.Conclusion： The expression of ST13 and BCL11B in peripheral blood may both serve as potential biomarkers for PD diagnosis,but the expression of BCL11B seems to be a better one since it displays a remarkable change at early stages of PD.

关 键 词：帕金森病 分子诊断 生物标记 BCL11B ST13 

分 类 号：R741[医药卫生—神经病学与精神病学] R741.04[医药卫生—临床医学]